养血柔肝丸治疗大鼠肝纤维化的实验研究  

Experimental study on the therapy of rats liver fibrosis with Yangxue Rougan pill

作　　者：张小丽[1] 张涛 李芳[1] 陈瑞明[1] 范引科[1] 成冬生[1] 高凤琴[1] ZHANG Xiaoli;ZHANG Tao;LI Fang;CHEN Ruiming;FAN Yinke;CHENG Dongsheng;GAO Fengqin(Shaanxi Provincial Academy of Traditional Chinese Medicine,Xi’an,Shaanxi,710003 P.R. China;Qinghua Deren Xi’an Pharmaceutical Co. Ltd.,Xi’an,Shaanxi,710043 P.R. China)

机构地区：[1]陕西省中医药研究院中药研究所,陕西西安710003 [2]清华德人西安幸福制药有限公司,陕西西安710043

出　　处：《华西药学杂志》2019年第5期448-452,共5页West China Journal of Pharmaceutical Sciences

基　　金：陕西省科技攻关项目(2016SF-324)

摘　　要：目的 研究养血柔肝丸对大鼠肝纤维化的治疗作用.方法 大鼠雌雄兼用,随机分为水对照组、模型组、养血柔肝丸组(25.0、12.5、6.25 g·kg-1)、扶正化瘀胶囊组.采用CCl4复制肝纤维化模型,按组别分别给药治疗,治疗结束后,取血,测定肝功能指标:谷丙转氨酶(ALT)、谷草转氨酶(AST)、胆红素(TBIL)、γ-谷氨酰基转移酶(GGT)、胆碱酯酶(CHE)、白蛋白(AlB);肝纤维化指标:透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原(PCⅢ)和Ⅳ型胶原(Ⅳ-C);摘取肝脏、脾脏,分别称重,并做病理组织学检查.结果 肝纤维化模型大鼠造模后,各组大鼠陆续出现竖毛和蜷缩,行动迟缓状态;肝脏重量和肝脏指数明显增加;脾脏重量和脾脏指数明显增加;大鼠血清中HA、LN、PCⅢ、Ⅳ、ALT、AST、TBIL、GGT、CHE的含量显著升高;ALB的含量显著降低;模型组的病理评分明显高于对照组,肝纤维化模型成立.给予养血柔肝丸治疗后,大鼠的竖毛和蜷缩、行动迟缓状态症状明显得到改善;大剂量的肝脏重量及中剂量的肝指数显著降低;3个剂量组均不同程度明显降低血清中HA、LN、PCⅢ、Ⅳ-C的含量;大、中剂量组均明显降低ALT、AST、TBIL、GGT、CHE的水平;各剂量组明显升高ALB的含量;养血柔肝丸大、中、小剂量组的病理评分明显降低.结论 养血柔肝丸对CCl4肝纤维化大鼠具有明显的治疗作用,起效剂量6.25 g·kg-1.OBJECTIVE To study the therapy of rats liver fibrosis with Yangxue Rougan pill( YRP). METHODS Half male and female rats were separated randomly into water control group,model group,group of 3 doses of YRP: 25. 0,12. 5,6. 25 g·kg^-1,Fuzheng Huayu capsule group. We duplicate liver fibrosis model by CCl4,and treat each group separately. Indices of liver function( ALT,AST,TBIL,GGT,CHE,Al B) and indices of liver fibrosis( HA、LN、PC Ⅲ and Ⅳ-C) were measured. Rats liver and spleen were weighed,and histopathologic examination was also performed. RESULTS After modeling of liver fibrosis,rats in all group have the symptoms of hair erection and body curling,with slower activity. Weight and indices of liver and spleen increased significantly. Contents of HA,LN,PC Ⅲ,Ⅳ-C,ALT,AST,TBIL,GGT and CHE in serum of the rats increased significantly,while ALB decreased significantly. Pathologic score of model group was much higher than control group,which means the seccuss of liver fibrosis model. Treating rats with YRP,symptoms of hair erection and body curling,with slower activity were improved significantly. Liver weight of large dose group and indices of middle dose decreased. Content of HA,LN,PCⅢ,Ⅳ-C in serum obviously decreased in groups of 3 doses. Level of ALT,AST,TBIL,GGT and CHE in large and middle dose group significantly decreased. ALB of all groups of 3 doses significantly increased. For group of large,middle and small dose,pathologic score decreased significantly. CONCLUSION YRP is notably effective for the treatment of CCl4 induced liver fibrosis in rats,and the minimum dose is 6. 25 g·kg-1.

关 键 词：养血柔肝丸 大鼠 四氯化碳 肝纤维化模型 肝纤维化 肝功能 肝纤维化4项 实验研究 

分 类 号：R96[医药卫生—药理学]